Leptin

Leptin (Ob Protein) — Adipose-Derived Satiety Hormone

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Strong

At a Glance

An endogenous metabolic hormone from adipose tissue that signals energy stores to the brain; metreleptin (MYALEPT) is its recombinant replacement therapy for complications of leptin deficiency in generalized lipodystrophy.

Plain English

Leptin is a signal made by fat tissue that helps the brain track stored energy. Levels normally rise as fat mass increases and fall with fat or energy loss. Common obesity generally does not represent simple leptin deficiency; its biology involves multiple factors, including reduced sensitivity to leptin in many people. Metreleptin is used for rare congenital or acquired generalized lipodystrophy with leptin deficiency, not as routine treatment for obesity.

Overview

Leptin is an adipose-derived hormone that helps signal energy stores to the hypothalamus, influencing appetite, energy homeostasis, and neuroendocrine physiology. Metreleptin is a recombinant leptin analog approved as MYALEPT for replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. MYALEPT is not a general obesity drug; common obesity involves more complex biology than simple leptin deficiency.

Research Summary

Leptin is an adipose-derived hormone that signals energy stores to the hypothalamus and helps regulate appetite, energy balance, and neuroendocrine physiology. Metreleptin is approved as replacement therapy for complications of leptin deficiency in congenital or acquired generalized lipodystrophy, a rare population distinct from common obesity. Long-term human evidence in generalized lipodystrophy demonstrated sustained improvements in glycemic control, triglycerides, and liver volume. Common obesity generally does not represent simple leptin deficiency; leptin resistance and other biological and environmental factors may contribute, and metreleptin is not an established treatment for common obesity.

Research Areas

  • Appetite regulation & energy homeostasis
  • Lipodystrophy treatment
  • Obesity & leptin resistance
  • Reproductive endocrinology
  • Immune modulation
  • Bone metabolism
  • Neuroinflammation

Safety & Risks

Serious Risks

  • Anti-metreleptin antibodies with neutralizing activity may inhibit endogenous leptin action and/or cause loss of MYALEPT efficacy; worsening metabolic control or severe infection has been reported
  • T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy both treated and not treated with MYALEPT; a causal relationship has not been established
  • Hypoglycemia can occur when MYALEPT is used with insulin or insulin secretagogues; dose adjustment and glucose monitoring may be required
  • Progression of autoimmune disorders has been observed with MYALEPT
  • Serious hypersensitivity reactions, including anaphylaxis, have been reported with MYALEPT

Reported Side Effects

  • Hypoglycemia, particularly when used with insulin or insulin secretagogues
  • Injection site reactions (bruising, erythema, hematoma)
  • Headache
  • Abdominal pain
  • Fatigue
  • Weight loss
United States
Leptin is a naturally occurring human hormone. Metreleptin (MYALEPT), a recombinant leptin analog, is FDA-approved as an adjunct to diet as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. MYALEPT is subject to the MYALEPT REMS program and is not approved for common obesity.
United Kingdom
Myalepta (metreleptin) EMA-approved for lipodystrophy; prescription only
Australia
Research only for general use; specialized access pathway only outside approved rare disease indications
Canada
Health Canada approved metreleptin for generalized lipodystrophy; prescription only

Citations & Sources